All the top Biotech & Pharma news in one daily newsletter.

What to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Looking to reach an audience of 1000+ biotech and pharma professionals? Let’s chat. 👍

THE GOOD
Approvals & Labels

Novaliq lands EC approval for Vevizye in dry eye disease
Small molecule, dry eye disease (keratoconjunctivitis sicca) - Read more

THE GOOD
Clinical Trials

Johnson & Johnson takes the ErLEADa against Pfizer, Astellas’ Xtandi in prostrate cancer, head-to-head study
Small molecule, prostrate cancer - Read more

Scandinavian Biopharma touts positive Ph2b ETVAX vaccine results in pediatric traveler’s diarrhea
Vaccine, enterotoxigenic Escherichia coli, traveler’s diarrhea - Read more

PDS Biotech showcases 36-month survival data in cervical cancer patients, Versamune® HPV + chemoradiation
Vaccine, cervical cancer - Read more

Synchron’s brain-computer interface implant shows no major adverse effects after a year
Medical device, brain-computer interface - Read more

THE GOOD
Fundraises

Frazier Life Sciences $630M Evergreen Public Fund
Venture capital, biotech investing - Read more

Integrated Biosciences $17M Seed raise
Small molecule, age-related diseases, AI - Read more

Rippl $23M Series A
Virtual health, dementia - Read more

LoQus23 Therapeutics £35M ($46.5M) Series A
Small molecule, Huntington’s - Read more

Triveni Bio $115M Series B
Antibody, atopic dermatitis, eczema - Read more

Nusano $115M Series C
Radiopharm, radioisotope manufacturing - Read more

Ostia Sciences CAD 1M ($740k) Seed raise
Probiotic, oral and respiratory microbiome - Read more

Wave Life Sciences closes upsized public offering, $230M gross proceeds
Oligonucleotide, RNA, Duchenne's muscular dystrophy, alpha-1 antitrypsin deficiency, Huntington’s disease - Read more

PRESENTED BY YOU?
Get 1000+ sets of biotech/pharma eyeballs on your product or service 👀

Looking to promote your biotech/pharma/life science-focused product or service to a captivated audience of industry professionals?

Consider sponsoring TLDR Biotech - your sponsored feature would go right here!

Ready to make a deal (or want more info)? Just reply to this email or message me on LinkedIn.

⬇️ The Good News (Cont’d) ⬇️

THE GOOD
Investments

Eli Lilly to invest a gargantuan $4.5B into new facility, Lilly Medicine Foundry, in Indiana
Drug development & manufacturing, manufacturing innovation - Read more

Johnson & Johnson also announces $2B towards new manufacturing plant in North Carolina
Manufacturing, supply chain - Read more

Aspen Neuroscience announces major cell therapy facility upgrade
Cell therapy, Parkinson’s disease, induced pluripotent stem cells - Read more

THE GOOD
Partnerships

Lundbeck, Charles River Laboratories partner on AI-enabled neurological drug discovery via CRL’s Logica platform (co-developed with Valo Health, a Flagship Pioneering-backed startup)
Drug discovery, neurological disease, central nervous system, AI - Read more

ReciPharm, Exela Pharma Sciences sign manufacturing facility cooperation
CDMO, manufacturing, biologics - Read more

Kedrion, Biotest sign “long-term strategic agreement” for US distribution of Yimmugo
Immunoglobulin, primary immunodeficiencies, distribution - Read more

ABL Bio, MSD (Merck & Co.) sign clinical trial collab involving ABL103 & Keytruda
Bispecific antibody, solid tumor - Read more

AstraZeneca, Owkin co-development pact for breast cancer screening tool
Pathology slide analysis, cancer screening, AI - Read more

THE GOOD
Patient Access

Gilead increases low- and middle-income country access to HIV antiretroviral lenacapavir via royalty-free licensing agreements
Small molecule, human immunodeficiency virus, antiretroviral - Read more

THE GOOD
Politics & Policy

US CMS pledges to meet with drugmakers “sooner” as part of next round of IRA drug pricing negotiations
Drug pricing, inflation reduction act - Read more [Paywall]

THE GOOD
Regulatory

EMA working to improve drug assessment and appproval process, current framework “not efficient enough“
Drug approval process, marketing authorization applications - Read more

THE GOOD
Research

Pharmacologically inactive nasal spray protects mice from respiratory pathogens; potential infectious disease prevention applications
Nasal spray, infectious disease - Read more

THE GOOD
Strategic Plans

BioNTech and their AI-powered acquisition InstaDeep provide updates on AI capabilities
Immunotherapy, drug discovery & development, AI - Read more

ENJOYING THESE NEWSLETTERS?
Support TLDR Biotech🧬🦠🔬 

I’m offering this newsletter for free so it can get out to as many people as possible.

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.*

*Best of all, it’s a work-related news source that you can likely expense. 😉 

THE BAD
Lawsuits

AbbVie, AstraZeneca, PhRMA take a big L in Louisiana 340B legal kerfuffle
340B drug pricing, community pharmacy - Read more

THE BAD
Layoffs

CVS cuts 2900 roles, mostly corporate, as “strategic review” rumors abound
Pharmacy, consumer health - Read more

ImmunityBio to layoff two staffers at Dunkirk plant
Cancer vaccine, manufacturing - Read more

Verrica Pharmaceuticals plans headcount reduction
Small molecule, molluscum contagiosum - Read more

THE BAD
Market Reports

As AI arms raise continues to escalate, tensions (and stark inequalities) may rise between AI-focused biotech and AI-invested Big Pharma; S&P Global report
Drug development, R&D, AI - Read more

THE UGLY
Withdrawals & Recalls

FDA escalates Philips ventilator recall to Class 1, critical software update
Medical device, ventilator, sleep apnea - Read more

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Last thing - if you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here